<div id="readability-page-1"><p>Sumitomo Mitsui Trust Holdings Inc. decreased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 10.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The firm owned 4,562,969 shares of the biopharmaceutical company's stock after selling 511,497 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned approximately 0.23% of Bristol-Myers Squibb worth $189,500,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Bristol-Myers Squibb</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 7/29 - 8/2</li></ul><p>Other large investors have also recently bought and sold shares of the company. Mackenzie Financial Corp raised its holdings in shares of Bristol-Myers Squibb by 37.9% during the fourth quarter. Mackenzie Financial Corp now owns 611,714 shares of the biopharmaceutical company's stock valued at $31,387,000 after purchasing an additional 168,135 shares during the period. Tyche Wealth Partners LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $349,000. Rakuten Securities Inc. bought a new stake in Bristol-Myers Squibb during the fourth quarter worth $44,000. Daiwa Securities Group Inc. grew its position in Bristol-Myers Squibb by 6.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 190,525 shares of the biopharmaceutical company's stock valued at $9,776,000 after buying an additional 12,160 shares during the period. Finally, Twin Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 13.4% in the 4th quarter. Twin Capital Management Inc. now owns 83,162 shares of the biopharmaceutical company's stock worth $4,267,000 after purchasing an additional 9,831 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Bristol-Myers Squibb Stock Performance</h2><p>Shares of NYSE:BMY traded up $0.25 during midday trading on Friday, reaching $49.36. 14,161,770 shares of the company's stock traded hands, compared to its average volume of 15,904,074. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The stock has a 50 day moving average of $43.74 and a 200 day moving average of $46.58. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The company has a market cap of $100.06 billion, a price-to-earnings ratio of -15.92, a P/E/G ratio of 12.51 and a beta of 0.44. </p><br/><ul><li>Pharma Giant's Shares Up After Impressive Q2 Earnings Release</li></ul><p>Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm had revenue of $12.20 billion during the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The business's revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year. </p><h2>Bristol-Myers Squibb Dividend Announcement</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.86%. Bristol-Myers Squibb's payout ratio is -77.42%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>3 High-Yield Dividend Stocks for Income Now and Growth Later</li></ul><p>BMY has been the topic of a number of recent research reports. BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a &#34;market perform&#34; rating on the stock in a research note on Friday, April 26th. StockNews.com upgraded Bristol-Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft cut their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a &#34;hold&#34; rating for the company in a report on Tuesday, July 23rd. TD Cowen lifted their price objective on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a &#34;hold&#34; rating in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated a &#34;neutral&#34; rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a report on Monday, July 22nd. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of &#34;Hold&#34; and an average target price of $54.86.</p><p><b>Get Our Latest Research Report on BMY</b></p><h2>Bristol-Myers Squibb Profile</h2> (Free Report)<p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Bristol-Myers Squibb</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>This Small Cap Wealth Management Stock Could Provide Big Returns</li><li>How to Capture the Benefits of Dividend Increases</li><li>Bumble's Valuation Hits an All-Time Low, Can Its Fortunes Change?</li><li>5 discounted opportunities for dividend growth investors</li><li>MarketBeat Week in Review – 8/12 - 8/16</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Elon to Transform U.S. Economy?  <span><span>(From Porter &amp; Company)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04ODY3"/></p><h2>Should you invest $1,000 in Bristol-Myers Squibb right now?</h2><p>Before you consider Bristol-Myers Squibb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol-Myers Squibb wasn't on the list.</p><p>While Bristol-Myers Squibb currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

<p>Sumitomo Mitsui Trust Holdings Inc. reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 10.1%, owning approximately 4.56 million shares worth $500 million after selling 511,497 shares. Bristol-Myers Squibb's shares have shown fluctuating performance, with analysts providing varied ratings and price targets. The company reported an EPS of $1.07 for Q2, beating estimates, and announced a quarterly dividend of $0.60, yielding 4.86%. Institutional investors hold 76.41% of the stock, reflecting significant interest in the biopharmaceutical firm.</p>

Sumitomo Mitsui Trust Holdings Inc. Has $189.50 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)